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Multiple sclerosis (MS) is an autoimmune disease caused by autoreactive T cells 
attacking myelin sheath proteins in nerve fibers of the central nervous system resulting 
in paralysis and death. Conventional T cells (cytolytic and helper) initiate disease in MS, 
and T regulatory cells (Tregs) are conventional T cell suppressors. By studying the 
development of Tregs, a T cell suppressor, we can stop T cells from attacking myelin 
sheath proteins and prevent disease progression. All T cells develop in the thymus in 
three stages: double negative, double positive, and single positive. In the stage of my 
research's interest, the double positive stage, the T cell undergoes two educational 
phases, positive and negative selection. In positive selection, an antigen presenting cell 
(APC) presents a peptide to the T cell's T cell receptor (TCR). If the interaction between 
the peptide on the APC and TCR has a low affinity, then the T cell survives. However, if 
the affinity between the peptide and the TCR is high, the T cell dies via apoptosis. We 
hypothesize that Tregs require a strong affinity between the peptide and TCR to 
continue to the next educational phase. Interestingly, exposure high affinity peptides 
resulted in a decrease in Treg apoptosis both in vitro and in vivo. This observation is 
opposite to conventional T cell selection. We want to determine the ability of medium 
affinity peptide, PLP-Y, to prevent Treg apoptosis in vitro because ex vivo analysis 
shows PLP-Y does prevent Treg apoptosis in the thymus. Our results from in vitro 
experiments, however, did not show prevention of Treg death. Thus, it is likely more 
peptide is needed to provide the signal strength necessary for prevention of Treg death. 
Since many autoimmune diseases arise from poor Treg development, a better 
knowledge of the selection process may lead to potential therapies. 
